Skip to main content

Table 2 Baseline, early and late post-biopsy HRQoL measurements

From: Health-related Quality of Life in Vacuum-Assisted Breast Biopsy: short-term effects, long-term effects and predictors

Variables Baseline
(mean ± SD)
Early post-biopsy measurement
(mean ± SD)
p§ Late post-biopsy measurement
(mean ± SD)
p Practical interpretation
EQ-5D dimensions and indices       
Mobility* 1.41 ± 0.49 1.42 ± 0.50 0.782 1.27 ± 0.45 0.011 Deterioration at baseline
Self-care* 1.03 ± 0.17 1.03 ± 0.17 1.000 1.09 ± 0.33 0.058 No changes
Usual activities* 1.24 ± 0.43 1.31 ± 0.46 0.021 1.23 ± 0.45 0.835 Short-term deterioration
Pain/discomfort* 1.53 ± 0.59 1.55 ± 0.61 0.977 1.71 ± 0.54 0.004 Long-term deterioration
Anxiety/depression* 1.98 ± 0.65 1.52 ± 0.61 <0.0001 1.77 ± 0.60 0.002 Deterioration at baseline
VAS "thermometer" 68.8 ± 18.4 67.5 ± 18.1 0.406 75.5 ± 15.6 0.003 Deterioration at baseline
EQ-5D index
(TTO method)
0.729 ± 0.224 0.787 ± 0.208 0.005 0.769 ± 0.225 0.251 Deterioration at baseline
EQ-5D index
(VAS method)
0.834 ± 0.076 0.854 ± 0.062 0.038 0.845 ± 0.085 0.324 Deterioration at baseline
SF-36 dimensions and scores       
Physical functioning 86.2 ± 19.5 85.2 ± 18.9 0.641 80.1 ± 19.4 0.0001 Long-term deterioration
Bodily pain 78.3 ± 26.4 76.3 ± 27.5 0.414 65.5 ± 30.5 0.0004 Long-term deterioration
General Health 64.5 ± 21.3 68.5 ± 22.5 0.067 65.6 ± 19.0 0.700 No changes
Vitality 60.6 ± 19.5 60.8 ± 18.7 0.999 59.6 ± 21.9 0.697 No changes
Social Functioning 75.3 ± 24.7 74.6 ± 25.3 0.496 73.4 ± 27.6 0.925 No changes
Mental Health 58.8 ± 19.3 60.4 ± 20.2 0.139 62.8 ± 21.1 0.030 Deterioration at baseline
Role functioning-physical 80.1 ± 33.1 72.3 ± 39.2 0.008 73.4 ± 39.0 0.098 Short-term deterioration
Role functioning-emotional 71.0 ± 37.0 70.9 ± 37.1 0.650 66.2 ± 42.1 0.347 No changes
Physical Component Scale 52.5 ± 8.6 51.8 ± 7.9 0.234 48.5 ± 9.3 0.004 Long-term deterioration
Mental Component Scale 40.1 ± 11.8 41.5 ± 11.6 0.270 41.9 ± 14.3 0.568 No changes
  1. § p-values derived from Wilcoxon matched-pairs signed-ranks test (early post-biopsy measurement vs. baseline)
  2. †: p-values derived from Wilcoxon matched-pairs signed-ranks test (late post-biopsy measurement vs. baseline)
  3. *: Measures where a higher score denotes a worse health status